Current Status and Future Directions of Molecular Genetics and Genetic Diseases

Dear Colleagues,

Molecular genetics has advanced rapidly over the past few decades, revolutionizing our understanding of genetic diseases and human biology. Today, technologies such as next-generation sequencing (NGS), genome-wide association studies (GWASs), and CRISPR-based genome editing have made it possible to identify disease-causing mutations with unprecedented accuracy and speed. These tools have improved diagnostic capabilities, enabled personalized medicine, and facilitated the development of targeted therapies for both rare and complex genetic disorders. Despite these achievements, challenges remain. Many genetic diseases still lack effective treatments, and the interpretation of variants of uncertain significance continues to limit clinical applications. Ethical issues, such as genetic privacy and germline editing, also require careful consideration as molecular genetics becomes more integrated into healthcare. Looking forward, this field is moving toward a future of precision medicine powered by artificial intelligence, large-scale genomic databases, and integrative “multi-omics” approaches that combine genomics, transcriptomics, proteomics, and metabolomics. Gene therapy, RNA-based treatments, and genome editing technologies hold great promise for correcting genetic defects at their source. Continued research, global collaboration, and responsible regulation will be crucial for ensuring that the benefits of molecular genetics are safely and equitably realized for all.

In this Special Issue, the following types of articles are welcome: original research articles, reviews and systematic reviews, communications, opinions, and perspectives.

We look forward to receiving your contributions.

Prof. Dr. Darko Katalinić
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.